Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraventricular Methotrexate for Recurrent Fourth Ventricular Brain Tumors
NCT02458339Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Jun 2015
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methotrexate in medulloblastoma, primitive neuroectodermal tumor (PNET), Atypical teratoid rhabdoid tumor (ATRT) and 2 more, sponsored by UTHealth Houston. Primary endpoint: Maximum Tolerated Dose at 3 months. Started Jun 2015; status: completed.
02
Drugs
methotrexate
03
Conditions
medulloblastomaprimitive neuroectodermal tumor (PNET)Atypical teratoid rhabdoid tumor (ATRT)ependymomachoroid plexus carcinoma (CPC)
Beyond the preview
Go deeper on NCT02458339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02458339.